Strong efficacy and cardiovascular benefits should allow Novo to continue growing sales of GLP-1 therapies in diabetes. While Novo lost share to Eli Lilly's once-weekly Trulicity, Ozempic and Rybelsus ...

Weaver outlined her concerns with counterfeit weight-loss medication. “If there is, contaminants, allergens in it, that sort ...

Eli Lilly is looking to approach regulatory approval of efsitora alfa (efsitora), its once-weekly insulin for type 2 diabetes ...

Madrigal Pharma's REZDIFFRA sees 33% Q1 2025 sales growth, strong EU progress, and promising MASH data. Read why I maintain ...

Budget impact analysis (BIA) plays a role in informing healthcare decision-making. BIA are typically conducted using short time horizons (2-5 years), and from the perspective of the budget holder (e.g ...

The race to develop muscle-preserving treatments alongside popular obesity drugs like Eli Lillys (NYSE:LLY) Zepbound and Novo ...

Analysts have projected that obesity drugs sales could reach $150 billion a year by the early 2030s. The unmet need to ...

Providing a diverse range of perspectives from bullish to bearish, 7 analysts have published ratings on Eli Lilly LLY -1.05% ...

McDonald’s has historically been a defensive play for investors because its menu appeals to budget-conscious consumers. However, expanded insurance coverage for GLP-1 drugs, along with discount ...

A new obesity drug combining four hormones may outperform Wegovy and Mounjaro. Learn what it means for health, science, and investors.

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results ...